Cargando…
The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902923/ https://www.ncbi.nlm.nih.gov/pubmed/36761773 http://dx.doi.org/10.3389/fimmu.2023.1082830 |
_version_ | 1784883364281450496 |
---|---|
author | Pan, Tuo Tuoerxun, Tayierjiang Chen, Xi Yang, Cheng-Jin Jiang, Chen-Yu Zhu, Yi-Fan Li, Ze-Shi Jiang, Xin-Yi Zhang, Hai-Tao Zhang, He Wang, Ya-Peng Chen, Wei Lu, Li-Chong Ge, Min Cheng, Yong-Qing Wang, Dong-Jin Zhou, Qing |
author_facet | Pan, Tuo Tuoerxun, Tayierjiang Chen, Xi Yang, Cheng-Jin Jiang, Chen-Yu Zhu, Yi-Fan Li, Ze-Shi Jiang, Xin-Yi Zhang, Hai-Tao Zhang, He Wang, Ya-Peng Chen, Wei Lu, Li-Chong Ge, Min Cheng, Yong-Qing Wang, Dong-Jin Zhou, Qing |
author_sort | Pan, Tuo |
collection | PubMed |
description | BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate the effect of sivelestat on pulmonary protection in patients with ALI after emergent cardiovascular surgery. METHODS: Firstly, a case-control study in 665 patients undergoing emergent cardiovascular surgery from January 1(st), 2020 to October 26(th), 2022 was performed. 52 patients who received sivelestat (0.2mg/kg/h for 3 days) and 613 age- and sex-matched controls. Secondly, a propensity-score matched cohort (sivelestat vs control: 50 vs 50) was performed in these 665 patients. The primary outcome was a composite of adverse outcomes, including 30-day mortality, ECMO, continuous renal replacement therapy (CRRT) and IABP, etc. The secondary outcome included pneumonia, ventricular arrhythmias and mechanical ventilation time, etc. RESULTS: In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01). CONCLUSION: Administration of sivelestat might improve postoperative outcomes in patients with ALI after emergent cardiovascular surgery. Our results show that sivelestat may be considered to protect pulmonary function against inflammatory injury by CPB. REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=166643, identifier ChiCTR2200059102. |
format | Online Article Text |
id | pubmed-9902923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99029232023-02-08 The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass Pan, Tuo Tuoerxun, Tayierjiang Chen, Xi Yang, Cheng-Jin Jiang, Chen-Yu Zhu, Yi-Fan Li, Ze-Shi Jiang, Xin-Yi Zhang, Hai-Tao Zhang, He Wang, Ya-Peng Chen, Wei Lu, Li-Chong Ge, Min Cheng, Yong-Qing Wang, Dong-Jin Zhou, Qing Front Immunol Immunology BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate the effect of sivelestat on pulmonary protection in patients with ALI after emergent cardiovascular surgery. METHODS: Firstly, a case-control study in 665 patients undergoing emergent cardiovascular surgery from January 1(st), 2020 to October 26(th), 2022 was performed. 52 patients who received sivelestat (0.2mg/kg/h for 3 days) and 613 age- and sex-matched controls. Secondly, a propensity-score matched cohort (sivelestat vs control: 50 vs 50) was performed in these 665 patients. The primary outcome was a composite of adverse outcomes, including 30-day mortality, ECMO, continuous renal replacement therapy (CRRT) and IABP, etc. The secondary outcome included pneumonia, ventricular arrhythmias and mechanical ventilation time, etc. RESULTS: In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01). CONCLUSION: Administration of sivelestat might improve postoperative outcomes in patients with ALI after emergent cardiovascular surgery. Our results show that sivelestat may be considered to protect pulmonary function against inflammatory injury by CPB. REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=166643, identifier ChiCTR2200059102. Frontiers Media S.A. 2023-01-24 /pmc/articles/PMC9902923/ /pubmed/36761773 http://dx.doi.org/10.3389/fimmu.2023.1082830 Text en Copyright © 2023 Pan, Tuoerxun, Chen, Yang, Jiang, Zhu, Li, Jiang, Zhang, Zhang, Wang, Chen, Lu, Ge, Cheng, Wang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Pan, Tuo Tuoerxun, Tayierjiang Chen, Xi Yang, Cheng-Jin Jiang, Chen-Yu Zhu, Yi-Fan Li, Ze-Shi Jiang, Xin-Yi Zhang, Hai-Tao Zhang, He Wang, Ya-Peng Chen, Wei Lu, Li-Chong Ge, Min Cheng, Yong-Qing Wang, Dong-Jin Zhou, Qing The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title | The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title_full | The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title_fullStr | The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title_full_unstemmed | The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title_short | The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
title_sort | neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902923/ https://www.ncbi.nlm.nih.gov/pubmed/36761773 http://dx.doi.org/10.3389/fimmu.2023.1082830 |
work_keys_str_mv | AT pantuo theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT tuoerxuntayierjiang theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chenxi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT yangchengjin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT jiangchenyu theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhuyifan theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT lizeshi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT jiangxinyi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhanghaitao theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhanghe theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT wangyapeng theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chenwei theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT lulichong theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT gemin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chengyongqing theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT wangdongjin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhouqing theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT pantuo neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT tuoerxuntayierjiang neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chenxi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT yangchengjin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT jiangchenyu neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhuyifan neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT lizeshi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT jiangxinyi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhanghaitao neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhanghe neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT wangyapeng neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chenwei neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT lulichong neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT gemin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT chengyongqing neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT wangdongjin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass AT zhouqing neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass |